---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-380194"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2026-09-02T20:11:16+00:00"
generated_at: "2026-09-02T20:12:07.854062+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences signs 5-year supply deal with Hovione for bezuclastinib manufacturing

## Summary
- Agreement with Hovione FarmaCiencia S.A. covers bezuclastinib spray-dried dispersion and tablets.
- Initial 5-year term with automatic 2-year renewals; minimum purchase percentages decrease over time.
- Quarterly forecasts; near-term portion binding, balance non-binding good-faith estimates.
- Termination rights include uncured breach, prolonged force majeure, insolvency, regulatory developments.
- Full agreement to be filed with Q3 2026 Form 10-Q.

## SEC filing metadata
- accession: 0001193125-26-380194
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2026-09-02T20:11:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/0001193125-26-380194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/d184156d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-380194
- JSON: https://secwatch.observer/filing/0001193125-26-380194.json
- Plain text: https://secwatch.observer/filing/0001193125-26-380194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.